Cytek Biosciences Inc (CTKB)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020
Gross profit (ttm)	US$ in thousands	111,106	110,502	108,675	111,401	109,426	105,752	105,436	101,835	100,974	95,236	89,760	84,944	79,253	75,066	69,296	57,821	51,710
Revenue (ttm)	US$ in thousands	176,629	201,210	197,710	200,786	193,014	183,117	175,594	166,060	164,036	154,594	148,493	138,742	127,950	119,675	110,395	99,123	92,839
Gross profit margin		62.90%	54.92%	54.97%	55.48%	56.69%	57.75%	60.05%	61.32%	61.56%	61.60%	60.45%	61.22%	61.94%	62.72%	62.77%	58.33%	55.70%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $111,106K ÷ $176,629K
= 62.90%

The gross profit margin of Cytek Biosciences Inc has shown some fluctuations over the periods provided in the data. Starting at 55.70% on December 31, 2020, the margin increased steadily up to June 30, 2021, reaching 62.77%. From September 30, 2021, to March 31, 2022, there was a slight decline, but the margin remained relatively high. However, from June 30, 2022, to September 30, 2024, there was a gradual decrease in the gross profit margin, dropping to 54.92% by September 30, 2024. Notably, by December 31, 2024, the margin rebounded significantly to 62.90%, indicating a potential recovery or improvement in the company's cost management or pricing strategies. Overall, while there have been fluctuations, Cytek Biosciences Inc has generally maintained a healthy gross profit margin over the periods covered in the data.